Navigation Links
Rutgers, UMDNJ receive $23 million to develop antidotes for chemical weapons attacks
Date:9/13/2011

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

Members of the Environmental and Occupational Health Sciences Institute (EOHSI), Rutgers and UMDNJ-Robert Wood Johnson Medical School have been collaborating with scientists from the School of Public Health at New York Medical College and the Chemistry Department at Lehigh University for the past five years to devise therapies that could be used if deadly chemical poisons were released into the general population.

The focus of the research is the development of drugs to treat individuals exposed to mustard gas. The newly awarded funding allows these investigators who are part of the UMDNJ/Rutgers CounterACT Research Center of Excellence the opportunity to continue work begun in 2006 after the NIH granted Rutgers and UMDNJ-Robert Wood Johnson Medical School $19.2 million to establish the center and begin its research.

"This funding allows our us to continue our considerable efforts with different research groups to develop drug products that can be used successfully against a chemical terrorist attack," said Jeffrey Laskin, Professor of Environmental and Occupational Medicine at Robert Wood Johnson Medical School, and director of the center. "This is critical to preventing serious injury and death from any such attack."

The focus of the center's research is the development of drug products to treat individuals exposed to mustard gas, which causes symptoms ranging from skin irritations and conjunctivitis to severe ulcerations, blistering of the skin, blindness and irreversible damage to the respiratory tract and lungs. Mustard gas was first used by the German military against Allied troops during World War I and more recently in the Iran-Iraq conflict during the 1980s. It is easy to make and transport and is still considered a high risk terrorist threat.

"We were asked if we could apply our expertise to help address this type of national security issue," said Laskin. "There has been a lot of conversation over the years about the problems that could result from a terrorist attack and everyone realized that we needed to develop a therapy to counteract this if it happens."

The principal investigators in the UMDNJ/Rutgers CounterACT Research Center of Excellence include Director Jeffrey Laskin of UMDNJ, Co-Director Donald Gerecke at Rutgers Ernest Mario School of Pharmacy, Marion Gordon, Debra Laskin and Patrick Sinko, also at Rutgers School of Pharmacy, Diane Heck at New York Medical College, and Ned Heindel at Lehigh University. They work closely with Batelle Laboratory in Ohio, where mustard gas experiments are carried out.


'/>"/>

Contact: Robin Lally
rlally@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. LCC science projects receive $1.2 million through WaterSMART program
3. NJIT professor working with graphene, carbon nanotubes to receive honor
4. Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa
5. Marine Science Institute receives $7 Million grant to study the impact of the Deepwater Horizon
6. UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship
7. Scientists receive grant to develop new DNA sequencing method
8. Hawaii receives funding for liver cancer research
9. CWRU School of Dental Medicine receives $2.6 million in grants
10. Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting
11. MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... 2, 2016 The immunohistochemistry (IHC) market ... a CAGR of 7.3% during the forecast period of 2016 to ... laboratories segment accounted for the largest share of immunohistochemistry (IHC) market, ... , ... immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies and ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology: